The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Genomic Health is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of GHDX and the rest of the Medical group's stocks.
Genomic Health is one of 761 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GHDX is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for GHDX's full-year earnings has moved 12.39% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, GHDX has gained about 57.46% so far this year. Meanwhile, stocks in the Medical group have gained about 2.52% on average. This means that Genomic Health is outperforming the sector as a whole this year.
Looking more specifically, GHDX belongs to the Medical - Biomedical and Genetics industry, which includes 281 individual stocks and currently sits at #107 in the Zacks Industry Rank. On average, this group has gained an average of 0.59% so far this year, meaning that GHDX is performing better in terms of year-to-date returns.
GHDX will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Genomic Health is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of GHDX and the rest of the Medical group's stocks.
Genomic Health is one of 761 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GHDX is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for GHDX's full-year earnings has moved 12.39% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, GHDX has gained about 57.46% so far this year. Meanwhile, stocks in the Medical group have gained about 2.52% on average. This means that Genomic Health is outperforming the sector as a whole this year.
Looking more specifically, GHDX belongs to the Medical - Biomedical and Genetics industry, which includes 281 individual stocks and currently sits at #107 in the Zacks Industry Rank. On average, this group has gained an average of 0.59% so far this year, meaning that GHDX is performing better in terms of year-to-date returns.
GHDX will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>